Journal article
Topical roflumilast for the treatment of psoriasis
Abstract
INTRODUCTION: New non-steroidal topical agents are needed for the treatment of psoriasis. Roflumilast cream 0.3% is a once daily phosphodiesterase-4 inhibitor that was recently approved by the FDA for the treatment of plaque psoriasis in adolescents and adults. It is indicated for use on all body surfaces including intertriginous areas.
AREAS COVERED: In this review, we summarize the current knowledge about roflumilast cream for the treatment …
Authors
Drakos A; Vender R; Torres T
Journal
Expert Review of Clinical Immunology, Vol. 19, No. 9, pp. 1053–1062
Publisher
Taylor & Francis
Publication Date
September 2, 2023
DOI
10.1080/1744666x.2023.2219897
ISSN
1744-666X